← Leaderboards
Piero D Dalerba
Columbia University Health Sciences
$1,898,273
Attributed
$1,898,273
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $380.7K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,898,273 · 1
By mechanism
R01$1,898,273 · 1
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Anil K Rustgi$51,275,906
- Robert J Wechsler-Reya$14,668,725
- Andrea Califano$71,130,512
- Ramon E Parsons$25,379,842
- Anna Lasorella$11,657,863
Others in their field
Other Emerging Leaders on “Drug Sensitivity”
- Michael-Christopher Keogh · Epicypher, Inc.$16,088,577
- Abraham Aizer Brody · New York University School Of Medicine$15,928,507
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$14,236,023
- Anna Upton · Global Alliance For Tb Drug Development$10,496,979
- Jeanette Coffin · Midwest Research Institute$10,204,323
- Bryan J Venters · Epicypher, Inc.$9,247,390
Research focus
Drug SensitivityDuct (Organ) StructureAcidsDrug Resistance3-DimensionalBiochemical PathwayAffectCancer CellAgonistCancer Stem CellAdenoid Cystic CarcinomaCellsCell TypeChemoradiationClinical TreatmentBiologicalCrispr/Cas TechnologyDesignDifferential ExpressionCancerousDistantDominant-Negative MutationDrug CombinationsElements
Grant awards (6)
Dissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs).$201,485
R01 · FY2023 · DE · contact PI
Dissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs)$178,670
R01 · FY2023 · DE · contact PI
Dissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs).$376,486
R01 · FY2022 · DE · contact PI
Dissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs).$380,419
R01 · FY2021 · DE · contact PI
Dissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs).$380,545
R01 · FY2020 · DE · contact PI
Dissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs).$380,668
R01 · FY2019 · DE · contact PI